| Dr Jeffrey Edward Goldberg, PHARMD | |
|
1525 W Park Ave, Anaconda, MT 59711-1829 | |
| (406) 563-8410 | |
| Not Available |
| Full Name | Dr Jeffrey Edward Goldberg |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1525 W Park Ave, Anaconda, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720355605 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 6866 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Edward Goldberg, PHARMD 2000 Tammany St, Anaconda, MT 59711-1752 Ph: (406) 560-1857 | Dr Jeffrey Edward Goldberg, PHARMD 1525 W Park Ave, Anaconda, MT 59711-1829 Ph: (406) 563-8410 |
News Archive
A George Washington University professor has designed new technology that can identify traces of chemicals at 10-19 moles, a previously undetectable amount. This minute quantity can be conceptualized as 10 times below a billionth of a billionth of a teaspoon of water.
A distinctly new type of methicillin resistant Staphylococcus aureus (MRSA) that is not detected by traditional genetic screening methods has been discovered in patients in Irish hospitals according to research to be published in the journal Antimicrobial Agents and Chemotherapy.
New CDC data shows that nearly one in five boys have a medical diagnosis of attention deficit hyperactivity disorder. Other public health issues highlighted by news outlets include stroke risks in younger people, prescription-drug deaths and OSHA policies.
In a recent study, researchers at Rhode Island Hospital found that fear of being rejected because of one's appearance, as well as rejection sensitivity to general interpersonal situations, were significantly elevated in individuals with Body Dysmorphic Disorder (BDD).
SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules' New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.
› Verified 6 days ago
Thomas Martin Volberding, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1300 E Park Ave, Anaconda, MT 59711 Phone: 406-563-9174 Fax: 406-563-9388 | |
Ms. Crystal Ida, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1300 E Park Ave, Anaconda, MT 59711 Phone: 406-563-5266 | |
Audrey F Walker, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1525 W Park Ave, Anaconda, MT 59711 Phone: 406-563-5383 | |
Cara M Dunkerson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 E Park Ave, Anaconda, MT 59711 Phone: 406-563-8441 Fax: 406-563-2956 | |
Dr. Judith Anne Schuelke, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1525 W Park Ave, Anaconda, MT 59711 Phone: 406-563-8410 Fax: 406-563-8438 | |
Mr. Michael D Richards, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 E Park Ave, Anaconda, MT 59711 Phone: 406-563-8441 Fax: 406-563-2956 |